NCT00055471 2012-10-31A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate CancerAstraZenecaPhase 2 Completed22 enrolled 17 charts